Zoetis Inc.

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, diagnostic products, and precision animal health solutions. The enterprise organizes operations into United States and International segments, offering therapies across companion animals and livestock. Core categories include parasiticides, dermatology, vaccines, anti-infectives, and pain management products, alongside diagnostics and genetic tests. The company serves veterinarians, livestock producers, and pet owners through direct sales, veterinary distributors, retail pharmacies, and e-commerce channels.

Headquartered in Parsippany, New Jersey, the company markets products directly in approximately 45 countries and sells into more than 100 countries across North America, Europe, Africa, Asia, Australia, and South America. Its operational footprint features a dedicated research and development headquarters in Kalamazoo, Michigan, and a network of 21 company-operated manufacturing sites across multiple continents, supplemented by more than 90 contract manufacturing organizations. The enterprise maintains global operations supported by approximately 3,900 sales and technical personnel and 1,700 research and development staff.

Summary of the business section of Zoetis's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had approximately 14,500 employees worldwide, which included approximately 6,800 employees in the U.S.”